Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 3 Neoplasms 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Rectal Neoplasms 2 Lung Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rhabdomyosarcoma 1 Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Hodgkin Disease 1 Hepatoblastoma 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms 1 Bites and Stings 1

Interventions

Cyclophosphamide 18 Dexamethasone 15 fludarabine 11 Rituximab 7 pomalidomide 6 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 carfilzomib 6 venetoclax 5 Lenalidomide 5 Gemcitabine 5 Cisplatin 5 Calcium Dobesilate 5 Nivolumab 4 Etoposide 4 Bortezomib 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cabazitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡